Kedrab Market Trends Are Creating New Opportunities For Industry Leaders
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Kedrab Market Size Forecast: How Large Could The Market Become By 2030?
The expansion observed during the historical period was driven by elevated rabies mortality rates, a dependence on immunoglobulin-based treatments, restricted availability of early vaccination, emergency public health response measures, and hospital-centered rabies care protocols.
The expansion of rabies prevention during the forecast period results from a higher number of animal bite cases, the spread of rabies awareness initiatives, the development of emergency care facilities, greater availability of monoclonal antibodies, and increased government funding. Key developments shaping this period involve the growing application of passive immunization for rabies, the broadening of post-exposure prophylaxis efforts, heightened attention to managing zoonotic diseases, a larger demand for emergency immunotherapy, and the reinforcement of public health response frameworks.
Download A Free Sample Report For Comprehensive Market Insights:
Kedrab Market Opportunity Drivers: What Is Creating New Revenue Potential?
The rising number of rabies cases is anticipated to propel growth in the kedrab market moving forward. Rabies, an almost invariably fatal illness resulting from contact with infected animals, represents a serious public health challenge, especially in areas where vaccine access is limited. This upward trend in rabies incidence can be attributed to insufficient vaccination of domestic animals, poor availability of post-exposure treatments, and the ongoing presence of the virus in wildlife populations, notably in underserved communities. Kedrab, a human rabies immunoglobulin, offers immediate passive immunity for individuals who have been exposed to the rabies virus, serving as a critical safeguard while active immunity builds through vaccination. As an illustration, the South Dakota Department of Health—a US government agency—reported in April 2024 that roughly 20 animals in South Dakota were confirmed to have rabies in 2023, marking a 122% increase compared to the 9 cases recorded in 2022. Consequently, the growing frequency of rabies incidents is driving demand in the kedrab market.
Kedrab Market Segment Breakdown: Which Categories Generate The Most Revenue?
The kedrab market covered in this report is segmented –
1) By Indication: Post-Exposure Prophylaxis For Rabies, Treatment For Patients Exposed To Suspected Rabid Animals
2) By Formulation: Injectable Formulation, Lyophilized Powder For Reconstitution
3) By Route Of Administration: Intramuscular Injection, Subcutaneous Injection
4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Emergency Departments, Specialty Clinics, Public Health Organizations
Kedrab Market Innovation Trends Driving Future Development
Key players within the kedrab market are actively pursuing innovative developments and securing regulatory frameworks, including exclusive licensing and distribution continuation notices, aimed at strengthening KEDRAB’s commercial footprint and market influence in the United States. An exclusive licensing and distribution continuation notice serves as an official document from a pharmaceutical or biotechnology firm, indicating that a prior agreement granting sole rights to license, distribute, or market a particular product has been prolonged or renewed. A notable example occurred in July 2023, when Kamada Ltd., an Israeli company specializing in plasma-derived biopharmaceuticals, revealed that Kedrion Biopharma had chosen to extend the exclusive U.S. distribution contract for KEDRAB, a human rabies immune globulin intended for post-exposure prophylaxis. KEDRAB delivers rapid passive immunity against rabies following possible exposure, backed by proven effectiveness, a strong safety profile, and regulatory endorsement in the United States. This two-year renewal ensures ongoing product availability and stable supply, bolstering Kedrion’s distribution network and strategic position in the U.S. immunoglobulin sector, thereby improving patient access and reinforcing public health preparedness.
Kedrab Market Key Players And Strategic Industry Positioning
Major companies operating in the kedrab market are Kamada Ltd., Kedrion Biopharma Inc.
Access The Complete Kedrab Market Report:
Kedrab Market Largest Region By Revenue And Market Share
North America was the largest region in the kedrab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kedrab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
